{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-026032","form_type":"8-K","ticker":"AKTX","cik":"0001541157","company_name":"Akari Therapeutics Plc","filed_at":"2025-08-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.284525+00:00","generated_at":"2026-05-17T09:12:34.738405+00:00","sec_items":["1.01","3.02","5.02","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Akari Therapeutics enters $25M ELOC with White Lion Capital; CFO resigns","bullets":["Entered $25M equity line with White Lion Capital; commitment period through Aug 29, 2028.","Pricing options include 97% of lowest price in 2-hour window or 20% discount if price below opening.","CFO Torsten Hombeck resigns effective Oct 10, 2025; will consult through Nov 30 for transition.","Company must file S-1 resale registration within 30 days; Exchange Cap at 19.99% of outstanding shares.","Floor price set at $0.20 per ADS; beneficial ownership limit 4.99% (may increase to 9.99% with notice)."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-026032","json":"https://secwatch.observer/filing/0001641172-25-026032.json","markdown":"https://secwatch.observer/filing/0001641172-25-026032.md","text":"https://secwatch.observer/filing/0001641172-25-026032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1541157/000164117225026032/0001641172-25-026032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1541157/000164117225026032/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T09:12:34.738405+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}